MSLN and cancer: In our study, we have characterised the expression of the tumour differentiation antigen mesothelin in these cancer types and demonstrated the efficacy of the mesothelin‐targeted hYP218 CAR T cells in gastric and colorectal cell lines and tumour xenografts.